Chloroquine and Hydroxychloroquine News – The U.S. Food and Drug Administration (FDA) has revoked its Emergency Use Authorization (EUA) regarding chlroquine and hydroxychloroquine as it has been found that these drugs do not effectively treat COVID-19.
Chloroquine and Hydroxychloroquine Information
On June 15, 2020, the FDA issued a letter revoking its EUA for hydroxychloroquine and chloroquine as to treatment for COVID-19. The FDA has based this revocation on facts that have become available throughout this pandemic. Clinical trial results have shown that hydroxychloroquine and chloroquine may not be effective in treating COVID-19 cases. In fact, it is noted that the possible benefits do not outweigh the potential and known risks.
This decision was issued after analysis of new and previously available information.
The FDA also advised in a different notice today that remdesivir should not be co-administered with chloroquine or hydroxychloroquine, as it could potentially reduce the effectiveness of remdesivir. It continues to be evaluated, but preliminary clinical trial results have shown that remdesivir can lead to a quicker recovery from COVID-19.
Contact The Weinberg Law Firm for a Free Pharmaceutical Drug Lawsuit Evaluation
If you or a loved one has been injured by a pharmaceutical drug and have a question regarding your legal rights, please call The Weinberg Law Firm toll free at 877-934-6274, or submit our easy-to use Lawsuit Evaluation Form today.
To learn about our additional legal services please see Medical Malpractice Lawsuit, Food Poisoning Attorney, and Pulmonary Embolism Lawyer.
